Based on these findings, we suggest that it could be beneficial to test patients with a range of motor neuron diseases, including dHMN, atypical and typical ALS, as well as (distal) myopathy and MSP phenotypes, for pathogenic HNRNPA1 variants. The gene discussed is HNRNPA1; the disease is amyotrophic lateral sclerosis.